Similarly, in non-small-cell lung cancer (NSCLC), high serum PD-L1 levels independently correlated with poor outcomes for patients who received chemotherapy as well as for those who were treated with ICI therapy. This evidence concerns the gene CD274 and non-small cell lung carcinoma.